Novavax (NVAX) 10-Q2015 Q1 Quarterly report

Filed: 7 May 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accessed, accessible, added, altogether, analytical, arise, Assembly, attack, attributed, aware, baby, blood, BMGF, body, breach, breached, care, cautionary, CDC, Certificate, challenge, Charter, childhood, content, criminal, cytotoxic, damage, decision, detailed, detrimental, devastation, disclosed, discover, disgruntled, disproportionately, disrupt, dominated, dramatically, EBOV, elicited, encouraged, ensure, Epidemiol, error, expeditiously, experienced, expertise, factor, failure, fall, fifty, fighting, foreseeable, Foundation, frequent, fusion, group, Hacker, hemagglutinin, hire, II, incapable, incentivize, innovative, intent, intrusion, kill, lease, legal, lethal, lost, low, maintenance, malfeasance, malware, Melinda, mild, moderate, necessitate, neuraminidase, newly, nucleic, ordinary, pathogen, percent, persist, personal, personally, practice, preclinical, privacy, promptly, proposal, quantify, readily, Recruitment, recurrent, refer, referred, rely, replicating, reproductive, reputation, reserved, resource, respond, restructure, reward, rolling, room, routine, saponin, scale, sensitive, sophistication, speak, stem, stockholder, stolen, store, stored, strategy, suffer, talented, threshold, toxicology, twelve, ultimately, unique, unrestricted, upcoming, valuable, vulnerable, waiting, Weekly, wheezing, wide

Removed: absence, acquired, acquisition, acutely, advancement, adverse, alum, announcement, assumed, attainment, attract, award, biopharmaceutical, biotechnology, blinded, carried, caution, chicken, Chinese, circulating, competition, complement, Controller, corroborated, deductible, delayed, directed, distinct, Egyptian, England, essentially, evidenced, Excluding, existence, expressing, extension, external, failed, formulation, fulfilling, gene, generated, HAI, highest, highlighted, IgG, improve, inadequate, independent, independently, inherent, injection, intramuscular, Isconova, issuable, Journal, launched, light, locking, maintain, marketed, MatrixTM, monoclonal, mutation, NDA, observed, operational, opposed, originally, outbreak, personnel, pharmaceutical, placebo, powerful, preventing, producing, prophylactic, prototype, publication, purified, rapid, reactogenicity, recommendation, reimburse, remain, retrospectively, revert, robust, rose, satisfactory, scientific, shortly, side, statistically, sustainable, tax, temporary, undetectable, unexercised, unexpected, utilize, validity, varying, virologist, widespread, younger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NVAX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT

TO 18 UNITED STATES C. §1350
(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report of Novavax, Inc. (the “Company”) on Form 10-Q for the fiscal period ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanley C. Erck, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report.

Date: May 7, 2015	By:	/s/ Stanley C. Erck
	President and Chief Executive Officer